Calidi Biotherapeutics, Inc. cash flow statement

In fiscal 2022, Calidi Biotherapeutics, Inc.'s operations generated −$13.2m of cash.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Calidi Biotherapeutics, Inc.: cash flow statement, annual
Fiscal year	2022Dec 2022
Cash from operations	−13
Depreciation and amortisation	0
Stock-based pay	5

US$ thousands unless shown otherwise. Fiscal quarters.

Calidi Biotherapeutics, Inc.: cash flow statement, quarterly
Quarter	2022 Q4Dec 2022
Cash from operations	−3,876
Depreciation and amortisation	98
Stock-based pay	1,058

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Calidi Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Calidi Biotherapeutics, Inc.